Forward Industries, Inc. - 10-Q Summary (Period Ended June 30, 2010)
Business Context and Reporting Period
Forward Industries, Inc. designs, markets, and distributes carry solutions (cases, bags, accessories) primarily for handheld electronic devices, including medical monitoring kits (diabetic products), cellular telephones, and bar code scanners. The company serves Original Equipment Manufacturers (OEMs) globally. This report covers the quarterly period ended June 30, 2010 (the "2010 Quarter") and the nine-month period ended June 30, 2010 (the "2010 Period").
Key Financial Metrics
| Metric | 2010 Quarter | 2009 Quarter | 2010 Period (9 Mo) | 2009 Period (9 Mo) |
|---|---|---|---|---|
| Net Sales | $5,058,392 | $4,106,814 | $13,604,845 | $13,670,407 |
| Gross Profit | $1,271,291 | $1,031,333 | $3,189,229 | $2,638,864 |
| Gross Margin | 25.1% | 25.1% | 23.4% | 19.3% |
| Operating Income (Loss) | $24,379 | ($126,176) | ($260,776) | ($1,237,150) |
| Net Income (Loss) | $17,000 | ($63,857) | ($282,180) | ($1,319,499) |
| Cash and Equivalents | $19,877,077 (as of June 30, 2010) | |||
| Working Capital | $22,307,884 (as of June 30, 2010) | |||
| Debt | No short or long-term debt outstanding |
Material Changes vs. Prior Period
- Quarterly Performance: The company returned to profitability in the 2010 Quarter with net income of $17,000, compared to a net loss of $64,000 in the prior year quarter. This was driven by a 23% increase in net sales to $5.1 million and a 23% increase in gross profit.
- Revenue Drivers: Sales of "Other Products" (non-diabetic) increased 59% to $1.6 million, while diabetic product sales increased 12% to $3.5 million. This slightly reduced the company's concentration in diabetic products (69% of sales vs. 76% prior year).
- Expense Trends: Operating expenses increased 8% in the quarter primarily due to a $175,000 increase in professional fees related to the adoption of a Shareholder Protection Rights Plan. This offset decreases in selling personnel costs.
- Nine-Month Performance: For the nine-month period, the net loss narrowed significantly to $282,000 from $1.3 million in the prior year, despite a slight 0.5% decline in total net sales. Gross profit improved 21% due to lower material costs and reduced Hong Kong operating expenses.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management is actively pursuing an acquisition or business combination to diversify the customer base and reduce concentration risk. A temporary Shareholder Protection Rights Plan was adopted in June 2010 in response to a Schedule 13D filing by LaGrange Capital Partners.
- Outlook: Management notes a modest pickup in sales orders from major diabetic customers but cites uncertainty regarding sustainability. The company continues to focus on expanding its customer and product base, noting preliminary success with new customers.
- Liquidity: The company maintains strong liquidity with approximately $19.9 million in cash and no debt. Current ratio is 8.2. Cash is primarily held in the U.S. and Europe, with a significant portion considered permanently invested earnings from the Swiss subsidiary.
- Risks: Key risks include high customer concentration (reliance on a few large OEMs), volatility in order flow, and the potential loss of key sales employees. The company also faces risks related to foreign currency fluctuations and the success of strategic alternatives.
- Contingencies: The Swiss subsidiary has a bank letter of guarantee up to approximately $92,000 (€75,000) for potential VAT liabilities in the Netherlands. No liability has been incurred as of June 30, 2010.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the top two diabetic customers, which accounted for the majority of the $3.5 million in diabetic sales for the quarter.
- One-Time Expenses: Confirm the impact of the $175,000 legal fee related to the Rights Plan on future operating expenses.
- Strategic Alternatives: Monitor progress on the announced search for an acquisition or business combination to diversify revenue streams.
- Inventory Levels: Review the increase in inventory ($1.05 million vs. $0.67 million prior year) to ensure it aligns with firm orders and does not indicate obsolescence risk.
- Foreign Currency Exposure: Assess the impact of Euro fluctuations on the company's European operations and receivables.